Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RY1 | P47900 | 8/20 | 0.79 |
| ▸ | P2RX3 | P56373 | 3/20 | 0.79 |
| ▸ | ENPP1 | P22413 | 2/20 | 0.79 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.79 |
| ▸ | P2RX4 | Q99571 | 2/20 | 0.79 |
| ▸ | P2RY11 | Q96G91 | 2/20 | 0.79 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.79 |
| ▸ | P2RY12 | Q9H244 | 1/20 | 0.77 |
| ▸ | NT5E | P21589 | 1/20 | 0.76 |
| ▸ | RNASEL | Q05823 | 2/20 | 0.74 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.73 |
| ▸ | SRC | P12931 | 1/20 | 0.73 |
| ▸ | P2RX2 | Q9UBL9 | 1/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.73 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.73 |
| ▸ | IMPDH2 | P12268 | 1/20 | 0.72 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.72 |
| ▸ | GPR17 | Q13304 | 2/20 | 0.72 |
| ▸ | CA5A | P35218 | 1/20 | 0.69 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29471291 | 1.00 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL13857854 | 1.00 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL18269547 | 1.00 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL12932283 | 1.00 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL17211052 | 1.00 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL3502237 | 1.00 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL16081048 | 0.93 | P2RX3 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL12932310 | 0.93 | P2RY1 (0.71) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL15794408 | 0.93 | P2RY1 (0.79) | P2RY1P2RX3ENPP1P2RX1P2RX4 | |
| SCHEMBL22224584 | 0.92 | P2RY1 (0.68) | P2RY1P2RX3ENPP1P2RX1P2RX4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1235 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | claimed |
| US-20250210148-A1 | METHOD OF PRODUCING DATA-ENCODED NUCLEIC ACID AND NUCLEIC ACID PRODUCED BY THE SAME | SAMSUNG ELECTRONICS CO., LTD. (KR) | 2025-06-26 | — | — | US | claimed |
| CN-119375375-A | Method for detecting nucleotide, cap analogue and nucleic acid in vitro transcription product | 楷拓生物科技(苏州)有限公司 | 2025-01-28 | — | — | CN | claimed |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | TRANSLATE BIO INC (US) | 2024-12-19 | — | — | US | claimed |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | TRANSLATE BIO, INC. (US) | 2024-06-04 | — | — | US | claimed |
| US-20220372158-A1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2022-11-24 | — | — | US | claimed |
| EP-3115064-B1 | RNA-CODED ANTIBODY | CUREVAC AG (DE) | 2021-11-24 | — | — | EP | claimed |
| US-11110156-B2 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen | CUREVAC AG (DE) | 2021-09-07 | — | — | US | claimed |
| US-20210060175-A1 | METHODS OF IMMUNOSTIMULATION WITH COMPLEXES OF RNA AND CATIONIC CARRIERS | CUREVAC AG (DE) | 2021-03-04 | — | — | US | claimed |
| US-20210060181-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED THERAPEUTIC PROTEIN | CUREVAC AG (DE) | 2021-03-04 | — | — | US | claimed |
| EP-2451980-B1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TRILINK BIOTECHNOLOGIES (US) | 2014-05-21 | — | — | EP | claimed |
| US-8728725-B2 | Chemically modified ligase cofactors, donors and acceptors | TRILINK BIOTECHNOLOGIES (US) | 2014-05-20 | — | — | US | claimed |
| US-20130195867-A1 | RNA-CODED ANTIBODY | CUREVAC GMBH (DE) | 2013-08-01 | — | — | US | claimed |
| US-20110008788-A1 | CHEMICALLY MODIFIED LIGASE COFACTORS, DONORS AND ACCEPTORS | TriLink Bio Technologies | 2011-01-13 | — | — | US | claimed |
| US-20100189729-A1 | RNA-CODED ANTIBODY | CURVAC GMBH (DE) | 2010-07-29 | — | — | US | claimed |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2010-02-25 | — | — | US | claimed |
| EP-2083851-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | Curevac GmbH (DE) | 2009-08-05 | — | — | EP | claimed |
| WO-2008052770-A2 | (BASE-)MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | CUREVAC GMBH (DE) | 2008-05-08 | — | — | WO | claimed |
| EP-1624059-A2 | Method of producing nucleic acid molecules with reduced secondary structure | Agilent Technologies, Inc. (US) | 2006-02-08 | — | — | EP | claimed |
| US-20040086880-A1 | Method of producing nucleic acid molecules with reduced secondary structure | AGILENT TECHNOLOGIES, INC. | 2004-05-06 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210060181-A1 | NUCLEIC ACID COMPRISING OR CODING FOR A HISTONE STEM-LOOP AND A POLY(A) SEQUENCE OR A POLYADENYLATION SIGNAL FOR INCREASING THE EXPRESSION OF AN ENCODED THERAPEUTIC PROTEIN | HNRNPH3, CPSF6, HNRNPL | P2RY1 2048/4885P2RX3 1904/4885ENPP1 2122/4885 |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | P2RY1 2831/4885P2RX3 2043/4885ENPP1 2442/4885 |
| US-20100047261-A1 | BASE-MODIFIED RNA FOR INCREASING THE EXPRESSION OF A PROTEIN | RNMT, RNASE1, NSUN3 | P2RY1 4557/4885P2RX3 4449/4885ENPP1 905/4885 |
| US-20240415958-A1 | MESSENGER RNA THERAPY FOR TREATMENT OF ARTICULAR DISEASE | NSUN3, RNMT, TRDMT1 | P2RY1 3509/4885P2RX3 2826/4885ENPP1 1221/4885 |
| US-11998601-B2 | Messenger RNA therapy for treatment of articular disease | NSUN3, RNMT, TRDMT1 | P2RY1 3509/4885P2RX3 2826/4885ENPP1 1221/4885 |
| US-11110156-B2 | Nucleic acid comprising or coding for a histone stem-loop and a poly(a) sequence or a polyadenylation signal for increasing the expression of an encoded tumour antigen | HNRNPH3, HNRNPL, CPSF6 | P2RY1 1808/4885P2RX3 1525/4885ENPP1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.